Dyno Therapeutics Inc.

AI-powered developer of synthetic AAV-like capsids for more effective gene therapy

Dyno Therapeutics was launched in 2018 by Eric Kelsic based on post-doc research completed with George Church at Harvard. The company is optimizing Adeno-Associated Virus ("AAV") capsids to enable the potential of gene therapies by synthetically engineering more effective in vivo delivery vehicles. These synthetic AAV capsids are designed using AI technologies to evade the human immune system, carry larger payloads, precisely deliver therapies to pre-defined targets, and to be more cost-effectively manufactured.